Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:12:23.806Z.
Calculation as of: 2026-10-06T14:12:23.806Z.
Quote observation: 2026-10-06T14:06:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8a37bf5da35164cf1f35689d787409f81d347c26e3158920307b7793dc95150d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$56.29M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $58.91M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.97M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $58.80M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.31M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.64M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $56.65M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $55.97M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.29M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $62.78M | N/A | 7.83x | 18.88x | 17.80x |
| Apollomics, Inc. (APLM)vs › | $53.17M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
